| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xinchi Feng, Xin Wang, Youping Liu, Xin D. Linarin Inhibits the Acetylcholinesterase Activity In-vitro and Ex-vivo. Iranian journal of pharmaceutical research : IJPR. vol 14. issue 3. 2015-09-02. PMID:26330885. |
in view of its potent ache inhibitory activity, linarin may be a promising therapeutic agent for the treatment of some diseases associated with ache, such as glaucoma, myasthenia gravis, gastric motility and alzheimer's disease. |
2015-09-02 |
2023-08-13 |
mouse |
| Shuai Qian, Lisi He, Marvin Mak, Yifan Han, Chun-Yu Ho, Zhong Zu. Synthesis, biological activity, and biopharmaceutical characterization of tacrine dimers as acetylcholinesterase inhibitors. International journal of pharmaceutics. vol 477. issue 1-2. 2015-08-24. PMID:25445524. |
tacrine (tha), as the first approved acetylcholinesterase (ache) inhibitors for the treatment of alzheimer's disease (ad), has been extensively investigated in last seven decades. |
2015-08-24 |
2023-08-13 |
Not clear |
| Armando Méndez-Garrido, Maricarmen Hernández-Rodríguez, Rafael Zamorano-Ulloa, José Correa-Basurto, Jessica Elena Mendieta-Wejebe, Daniel Ramírez-Rosales, Martha Cecilia Rosales-Hernánde. In vitro effect of H2O 2, some transition metals and hydroxyl radical produced via fenton and fenton-like reactions, on the catalytic activity of AChE and the hydrolysis of ACh. Neurochemical research. vol 39. issue 11. 2015-07-29. PMID:25096900. |
it is well known that the principal biomolecules involved in alzheimer's disease (ad) are acetylcholinesterase (ache), acetylcholine (ach) and the amyloid beta peptide of 42 amino acid residues (aβ42). |
2015-07-29 |
2023-08-13 |
Not clear |
| Gohar Mushtaq, Nigel H Greig, Jalaluddin A Khan, Mohammad A Kama. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. CNS & neurological disorders drug targets. vol 13. issue 8. 2015-07-02. PMID:25345511. |
both alzheimer's disease (ad) and type 2 diabetes mellitus (t2dm) share the presence of systemic and neuro-inflammation, enhanced production and accumulation of β -amyloid peptide and abnormal levels of the enzymes acetylcholinesterase (ache) and butyrylcholinesterase (buche). |
2015-07-02 |
2023-08-13 |
Not clear |
| Christophe Rochais, Cédric Lecoutey, Florence Gaven, Patrizia Giannoni, Katia Hamidouche, Damien Hedou, Emmanuelle Dubost, David Genest, Samir Yahiaoui, Thomas Freret, Valentine Bouet, François Dauphin, Jana Sopkova de Oliveira Santos, Céline Ballandonne, Sophie Corvaisier, Aurélie Malzert-Fréon, Remi Legay, Michel Boulouard, Sylvie Claeysen, Patrick Dallemagn. Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride. Journal of medicinal chemistry. vol 58. issue 7. 2015-06-30. PMID:25793650. |
novel multitarget-directed ligands (mtdls) with acetylcholinesterase (ache) inhibitory and serotonergic subtype 4 receptor (5-ht4r) agonist activities as potential agents against alzheimer's disease: the design of donecopride. |
2015-06-30 |
2023-08-13 |
mouse |
| Tadashi Watabe, Sadahiro Naka, Hayato Ikeda, Genki Horitsugi, Yasukazu Kanai, Kayako Isohashi, Mana Ishibashi, Hiroki Kato, Eku Shimosegawa, Hiroshi Watabe, Jun Hatazaw. Distribution of intravenously administered acetylcholinesterase inhibitor and acetylcholinesterase activity in the adrenal gland: 11C-donepezil PET study in the normal rat. PloS one. vol 9. issue 9. 2015-06-22. PMID:25225806. |
acetylcholinesterase (ache) inhibitors have been used for patients with alzheimer's disease. |
2015-06-22 |
2023-08-13 |
rat |
| M R Islam, S Moriguchi, H Tagashira, K Fukunag. Rivastigmine improves hippocampal neurogenesis and depression-like behaviors via 5-HT1A receptor stimulation in olfactory bulbectomized mice. Neuroscience. vol 272. 2015-05-11. PMID:24797332. |
rivastigmine is a non-competitive inhibitor of both acetylcholinesterase (ache) and butylcholinesterase (buche) used to treat mild to moderate dementia in alzheimer's disease (ad) patients. |
2015-05-11 |
2023-08-13 |
mouse |
| María Dolores López, Francisco J Campoy, María Jesús Pascual-Villalobos, Encarnación Muñoz-Delgado, Cecilio J Vida. Acetylcholinesterase activity of electric eel is increased or decreased by selected monoterpenoids and phenylpropanoids in a concentration-dependent manner. Chemico-biological interactions. vol 229. 2015-04-27. PMID:25636489. |
the previously unnoticed increase in ache activity with monoterpenoids should be considered as a reminder when advising the use of essential oils of plants or their constituents as anti-ache agents to attenuate pathological signs of alzheimer's disease. |
2015-04-27 |
2023-08-13 |
Not clear |
| Christina E Turi, Katarina E Axwik, Anderson Smith, A Maxwell P Jones, Praveen K Saxena, Susan J Murc. Galanthamine, an anticholinesterase drug, effects plant growth and development in Artemisia tridentate Nutt. via modulation of auxin and neutrotransmitter signaling. Plant signaling & behavior. vol 9. issue 3. 2015-04-21. PMID:24690897. |
galanthamine is a naturally occurring acetylcholinesterase (ache) inhibitor that has been well established as a drug for treatment of mild to moderate alzheimer disease, but the role of the compound in plant metabolism is not known. |
2015-04-21 |
2023-08-13 |
Not clear |
| Houria Berhail Boudouda, Assia Zeghib, Anastazia Karioti, Anna Rita Bilia, Mehmet Öztürk, Mahjoub Aouni, Ahmed Kabouche, Zahia Kabouch. Antibacterial, antioxidant, anti-cholinesterase potential and flavonol glycosides of Biscutella raphanifolia (Brassicaceae). Pakistan journal of pharmaceutical sciences. vol 28. issue 1. 2015-04-20. PMID:25553679. |
since there is a relationship between antioxidants and cholinesterase enzyme inhibitors, we used two methods to determine the in vitro anti-cholinesterase activity by the use of the basic enzymes that occur in causing alzheimer's disease: acetylcholinesterase (ache) and butyrylcholinesterase (bche). |
2015-04-20 |
2023-08-13 |
human |
| María-Letizia Campanari, María-Salud García-Ayllón, Lidia Blazquez-Llorca, Wilson K W Luk, Karl Tsim, Javier Sáez-Valer. Acetylcholinesterase protein level is preserved in the Alzheimer's brain. Journal of molecular neuroscience : MN. vol 53. issue 3. 2015-04-06. PMID:24318838. |
acetylcholinesterase (ache) is a key enzyme in the cholinergic nervous system and is one of the most studied proteins in the field of alzheimer's disease (ad). |
2015-04-06 |
2023-08-12 |
Not clear |
| Rahul P Modh, Sivakumar Prasanth Kumar, Yogesh T Jasrai, Kishor H Chikhali. Design, synthesis, biological evaluation, and molecular modeling of coumarin-piperazine derivatives as acetylcholinesterase inhibitors. Archiv der Pharmazie. vol 346. issue 11. 2015-04-06. PMID:24591157. |
acetylcholinesterase (ache) is an important drug target for the treatment of alzheimer's disease. |
2015-04-06 |
2023-08-12 |
human |
| Qi Sun, Da-Yong Peng, Sheng-Gang Yang, Xiao-Lei Zhu, Wen-Chao Yang, Guang-Fu Yan. Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase. Bioorganic & medicinal chemistry. vol 22. issue 17. 2015-04-06. PMID:25088549. |
exploring small-molecule acetylcholinesterase (ache) inhibitors to slow the breakdown of acetylcholine (ach) represents the mainstream direction for alzheimer's disease (ad) therapy. |
2015-04-06 |
2023-08-13 |
human |
| Adriana Ferreira Lopes Vilela, Joyce Izidoro da Silva, Lucas Campos Curcino Vieira, Gilberto C R Bernasconi, Arlene Gonçalves Corrêa, Quezia Bezerra Cass, Carmen Lúcia Cardos. Immobilized cholinesterases capillary reactors on-flow screening of selective inhibitors. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. vol 968. 2015-03-31. PMID:24321276. |
the discovery of selective inhibitors for acetylcholinesterase (ache) or butyrylcholinesterase (bche) is extremely important for the development of drugs that can be used in the treatment of patients diagnosed with the alzheimer's disease (ad). |
2015-03-31 |
2023-08-12 |
Not clear |
| Sijie Liu, Ruofeng Shang, Lanxiang Shi, Ran Zhou, Jingyu He, David Chi-Cheong Wa. Design, synthesis, and evaluation of 7H-thiazolo-[3,2-b]-1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors. Chemical biology & drug design. vol 84. issue 2. 2015-03-09. PMID:24890706. |
new dual binding site acetylcholinesterase (ache) inhibitors have been designed and synthesized as a new drug candidate for the treatment of alzheimer's disease (ad) through the binding to both catalytic and peripheral sites of the enzyme. |
2015-03-09 |
2023-08-13 |
human |
| Miroslav Pohank. Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. International journal of molecular sciences. vol 15. issue 6. 2015-01-29. PMID:24893223. |
acetylcholinesterase (ache) inhibitors are widely used for the symptomatic treatment of alzheimer's disease and other dementias. |
2015-01-29 |
2023-08-13 |
Not clear |
| Miroslav Pohanka, Martina Hrabinova, Kamil Kuca, Jean-Pierre Simonat. Assessment of acetylcholinesterase activity using indoxylacetate and comparison with the standard Ellman's method. International journal of molecular sciences. vol 12. issue 4. 2015-01-22. PMID:21731462. |
assay of acetylcholinesterase (ache) activity plays an important role in diagnostic, detection of pesticides and nerve agents, in vitro characterization of toxins and drugs including potential treatments for alzheimer's disease. |
2015-01-22 |
2023-08-12 |
Not clear |
| Sung Ryul Lee, Julius Ryan D Pronto, Bolor-Erdene Sarankhuu, Kyung Soo Ko, Byoung Doo Rhee, Nari Kim, Natalia P Mishchenko, Sergey A Fedoreyev, Valentin A Stonik, Jin Ha. Acetylcholinesterase inhibitory activity of pigment echinochrome A from sea urchin Scaphechinus mirabilis. Marine drugs. vol 12. issue 6. 2015-01-15. PMID:24918454. |
acetylcholinesterase (ache) inhibitors are used in the treatment of various neuromuscular disorders, and are considered as strong therapeutic agents for the treatment of alzheimer's disease (ad). |
2015-01-15 |
2023-08-13 |
Not clear |
| Syed M D Rizvi, Shahnawaz Shakil, Deboshree Biswas, Shazi Shakil, Sibhghatulla Shaikh, Paramdeep Bagga, Mohammad A Kama. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. CNS & neurological disorders drug targets. vol 13. issue 3. 2015-01-07. PMID:24059302. |
acetylcholinesterase (ache) is a primary target for alzheimer's therapy while recently sodium glucose cotransporter 2 (sglt2) has gained importance as a potential target for type 2 diabetes mellitus (t2dm) therapy. |
2015-01-07 |
2023-08-12 |
Not clear |
| Syed M D Rizvi, Shahnawaz Shakil, Deboshree Biswas, Shazi Shakil, Sibhghatulla Shaikh, Paramdeep Bagga, Mohammad A Kama. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. CNS & neurological disorders drug targets. vol 13. issue 3. 2015-01-07. PMID:24059302. |
the present study emphasizes the molecular interactions between a new food and drug administration (fda) approved antidiabetic drug 'invokana' (chemically known as canagliflozin) with ache and sglt2 to establish a link between the treatment of t2dm and alzheimer's disease (ad). |
2015-01-07 |
2023-08-12 |
Not clear |